NCT05002127Phase 2, phase 3Completed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Study sponsor: ALX Oncology Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-05-24Actual
Enrollment · participants127Actual
Source updated2026-11-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview